{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:44:20Z","timestamp":1788057860737,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>While three-dimensional radiotherapy (RT) causes high incidental nodal doses in bladder-only irradiation for muscle-invasive bladder cancer (MIBC), the impact on pelvic lymphatics is unclear in the era of intensity-modulated RT (IMRT). This study evaluates incidental doses to pelvic lymphatics in MIBC patients treated with IMRT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The data of 40\u00a0MIBC patients treated with bladder-only IMRT and concurrent chemotherapy were retrospectively evaluated. The pelvic lymphatics were contoured on initial simulation images and incidental nodal doses were evaluated. The Statistical Package for the Social Sciences (SPSS) version\u00a023.0 (IBM, Armonk, NY, USA) was used for statistics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Median RT dose to the bladder was 60\u202fGy in 30\u00a0fractions. In dosimetric analysis, median values of mean dose (D<jats:sub>mean<\/jats:sub>) of the obturator, presacral, external iliac, internal iliac, and distal common iliac lymphatics were 33\u202fGy (range 4\u201350\u202fGy), 3\u202fGy (range 1\u201328\u202fGy), 9.5\u202fGy (range 3\u201341\u202fGy), 7.5\u202fGy (range 2\u201314\u202fGy), and 1\u202fGy (range 0\u201315\u202fGy), respectively. The D<jats:sub>mean<\/jats:sub> of the obturator lymphatics was significantly higher (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001) and the D<jats:sub>mean<\/jats:sub> of the distal common iliac lymphatics was significantly lower (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001) than all remaining lymphatic stations. The D<jats:sub>mean<\/jats:sub> of the external iliac lymphatics was significantly higher than that of the presacral lymphatics (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001), but the difference with the internal iliac lymphatics was not statistically significant (<jats:italic>p<\/jats:italic>\u202f=\u20090.563).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The incidental nodal doses with bladder-only IMRT are heterogeneous and remain below the generally accepted doses for microscopic disease eradication for bladder cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-024-02246-2","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T09:06:55Z","timestamp":1718701615000},"page":"501-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of incidental dose to pelvic nodes in bladder-only irradiation in the era of IMRT: a\u00a0dosimetric study"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-4348","authenticated-orcid":false,"given":"Gokhan","family":"Ozyigit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Kahvecioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazli Yagiz","family":"Yedekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"2246_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang\u00a0SS, Bochner\u00a0BH, Chou\u00a0R, Dreicer\u00a0R, Kamat\u00a0AM, Lerner\u00a0SP et\u00a0al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J\u00a0Urol 198:552\u2013559","journal-title":"J Urol"},{"key":"2246_CR2","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","volume":"361","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2003","unstructured":"Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a\u00a0systematic review and meta-analysis. Lancet 361:1927\u20131934","journal-title":"Lancet"},{"key":"2246_CR3","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak\u00a0RH, Hunt\u00a0D, Shipley\u00a0WU, Efstathiou\u00a0JA, Tester\u00a0WJ, Hagan\u00a0MP et\u00a0al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a\u00a0pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J\u00a0Clin Oncol 32:3801\u20133809","journal-title":"J Clin Oncol"},{"key":"2246_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta\u00a0AR, Ballas\u00a0LK, Niemierko\u00a0A, Lajkosz\u00a0K, Kuk\u00a0C, Miranda\u00a0G et\u00a0al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a\u00a0multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24:669\u2013681","journal-title":"Lancet Oncol"},{"key":"2246_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04506-9","author":"PL Reignier","year":"2023","unstructured":"Reignier\u00a0PL, Gauthier\u00a0H, Hennequin\u00a0C, Aussedat\u00a0Q, Xylinas\u00a0E, Desgrandchamps\u00a0F et\u00a0al (2023) Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer. World J Urol. https:\/\/doi.org\/10.1007\/s00345-023-04506-9","journal-title":"World J Urol"},{"key":"2246_CR6","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1200\/JCO.23.00725","volume":"41","author":"M Swinton","year":"2023","unstructured":"Swinton\u00a0M, Mariam\u00a0NBG, Tan\u00a0JL, Murphy\u00a0K, Elumalai\u00a0T, Soni\u00a0M et\u00a0al (2023) Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer. J\u00a0Clin Oncol 41:4406\u20134415","journal-title":"J Clin Oncol"},{"key":"2246_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semradonc.2022.10.004","volume":"33","author":"SC Kamran","year":"2023","unstructured":"Kamran\u00a0SC, Efstathiou\u00a0JA (2023) The legacy of RTOG\/NRG protocols in shaping current bladder preservation therapy in north america. Semin Radiat Oncol 33:26\u201334","journal-title":"Semin Radiat Oncol"},{"key":"2246_CR8","doi-asserted-by":"publisher","first-page":"272.e1","DOI":"10.1016\/j.urolonc.2021.12.015","volume":"40","author":"K Softness","year":"2022","unstructured":"Softness\u00a0K, Kaul\u00a0S, Fleishman\u00a0A, Efstathiou\u00a0J, Bellmunt\u00a0J, Kim\u00a0SP et\u00a0al (2022) Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol 40:272.e1\u2013e9","journal-title":"Urol Oncol"},{"key":"2246_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2021.06.011","volume":"161","author":"J Khalifa","year":"2021","unstructured":"Khalifa\u00a0J, Supiot\u00a0S, Pignot\u00a0G, Hennequin\u00a0C, Blanchard\u00a0P, Pasquier\u00a0D et\u00a0al (2021) Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiother Oncol 161:95\u2013114","journal-title":"Radiother Oncol"},{"key":"2246_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","volume":"82","author":"E Hall","year":"2022","unstructured":"Hall\u00a0E, Hussain\u00a0SA, Porta\u00a0N, Lewis\u00a0R, Crundwell\u00a0M, Jenkins\u00a0P et\u00a0al (2022) Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase\u00a03 randomised controlled BC2001 trial. Eur Urol 82:273\u2013279","journal-title":"Eur Urol"},{"key":"2246_CR11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James\u00a0ND, Hussain\u00a0SA, Hall\u00a0E, Jenkins\u00a0P, Tremlett\u00a0J, Rawlings\u00a0C et\u00a0al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N\u00a0Engl J Med 366:1477\u20131488","journal-title":"N Engl J Med"},{"key":"2246_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1533034617691409","volume":"16","author":"S Lewis","year":"2017","unstructured":"Lewis\u00a0S, Murthy\u00a0V, Mahantshetty\u00a0U, Shrivastava\u00a0SK (2017) Incidental dose to pelvic nodes in bladder-only radiotherapy: is it clinically relevant? Technol Cancer Res Treat 16:382\u2013387","journal-title":"Technol Cancer Res Treat"},{"key":"2246_CR13","doi-asserted-by":"publisher","first-page":"368.e19","DOI":"10.1016\/j.urolonc.2020.11.006","volume":"39","author":"P Hurmuz","year":"2021","unstructured":"Hurmuz\u00a0P, Ozyigit\u00a0G, Kilickap\u00a0S, Esen\u00a0CSB, Akdogan\u00a0B, Ozen\u00a0H et\u00a0al (2021) Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: may neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes? Urol Oncol 39:368.e19\u2013e29","journal-title":"Urol Oncol"},{"key":"2246_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.prro.2022.05.014","volume":"12","author":"F Verghote","year":"2022","unstructured":"Verghote\u00a0F, Sargos\u00a0P, Christodouleas\u00a0JP, Murthy\u00a0V, Baumann\u00a0BC, Dirix\u00a0P et\u00a0al (2022) International consensus guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy: update from an IBIS workgroup. Pract Radiat Oncol 12:524\u2013532","journal-title":"Pract Radiat Oncol"},{"key":"2246_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/MOU.0000000000001113","volume":"33","author":"M de Angelis","year":"2023","unstructured":"de Angelis\u00a0M, Basile\u00a0G, Scornajenghi\u00a0CM, Asero\u00a0V, Del Giudice\u00a0F, Moschini\u00a0M (2023) Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer. Curr Opin Urol 33:354\u2013359","journal-title":"Curr Opin Urol"},{"key":"2246_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.10.022","author":"K Bruck","year":"2023","unstructured":"Bruck\u00a0K, Meijer\u00a0RP, Boormans\u00a0JL, Kiemeney\u00a0LA, Witjes\u00a0JA, van Hoogstraten\u00a0LMC et\u00a0al (2023) Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a\u00a0nationwide study. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.euo.2023.10.022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2246_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/1748-717X-9-213","volume":"9","author":"CY Lee","year":"2014","unstructured":"Lee\u00a0CY, Yang\u00a0KL, Ko\u00a0HL, Huang\u00a0RY, Tsai\u00a0PP, Chen\u00a0MT et\u00a0al (2014) Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. Radiat Oncol 9:213","journal-title":"Radiat Oncol"},{"key":"2246_CR18","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.21873\/anticanres.14267","volume":"40","author":"A Adachi","year":"2020","unstructured":"Adachi\u00a0A, Kawamura\u00a0H, Yoshida\u00a0D, Kawahara\u00a0M, Kudo\u00a0S, Ebara\u00a0T et\u00a0al (2020) Whole-bladder radiation therapy for lymph node-negative bladder cancer with muscle invasion in elderly patients. Anticancer Res 40:2905\u20132909","journal-title":"Anticancer Res"},{"key":"2246_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3332\/ecancer.2016.682","volume":"10","author":"W Arafat","year":"2016","unstructured":"Arafat\u00a0W, Darwish\u00a0A, Naoum\u00a0GE, Sameh\u00a0W, Husseiny\u00a0GE, Abd-El-Gawad\u00a0F et\u00a0al (2016) Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients. ecancer 10:682","journal-title":"ecancer"},{"key":"2246_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijrobp.2017.04.009","volume":"99","author":"AA Solanki","year":"2017","unstructured":"Solanki\u00a0AA, Martin\u00a0B, Korpics\u00a0M, Small\u00a0C, Harkenrider\u00a0MM, Mitin\u00a0T (2017) Bladder-preserving therapy patterns of care: a\u00a0survey of US radiation oncologists. Int J Radiat Oncol Biol Phys 99:383\u2013387","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2246_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.hoc.2014.10.004","volume":"29","author":"AB Jani","year":"2015","unstructured":"Jani\u00a0AB, Efstathiou\u00a0JA, Shipley\u00a0WU (2015) Bladder preservation strategies. Hematol Oncol Clin North Am 29:289\u2013300","journal-title":"Hematol Oncol Clin North Am"},{"key":"2246_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ijrobp.2012.03.061","volume":"85","author":"BC Baumann","year":"2013","unstructured":"Baumann\u00a0BC, Guzzo\u00a0TJ, He\u00a0J, Vaughn\u00a0DJ, Keefe\u00a0SM, Vapiwala\u00a0N et\u00a0al (2013) Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 85:363\u2013369","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2246_CR23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/1097-0142(197206)29:6<1450::AID-CNCR2820290605>3.0.CO;2-Q","volume":"29","author":"GH Fletcher","year":"1972","unstructured":"Fletcher\u00a0GH (1972) Elective irradiation of subclinical disease in cancers of the head and neck. Cancer 29:1450\u20131454","journal-title":"Cancer"},{"key":"2246_CR24","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1002\/1097-0142(19901215)66:12<2498::AID-CNCR2820661209>3.0.CO;2-X","volume":"66","author":"LB Marks","year":"1990","unstructured":"Marks\u00a0LB (1990) A\u00a0standard dose of radiation for \u201cmicroscopic disease\u201d is not appropriate. Cancer 66:2498\u20132502","journal-title":"Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02246-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T09:49:55Z","timestamp":1745315395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02246-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2246"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02246-2","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.\u00a0Ozyigit, A.\u00a0Kahvecioglu, M.\u00a0Cengiz, F.Y.\u00a0Yedekci, and P.\u00a0Hurmuz declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval and consent to participate: Available. Ethical approval number is SBA 24\/113.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}